Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, single-institution, modern cohort study

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Background: Recurrent head and neck cancer has poor prognosis. Stereotactic body radiotherapy (SBRT) may improve outcomes by delivering ablative radiation doses. Methods: We reviewed patients who received definitive-intent SBRT reirradiation at our institution from 2013 to 2020. Patterns of failure, overall survival (OS), and toxicities were analyzed. Results: One hundred and thirty-seven patients were evaluated. The median OS was 44.3 months. The median SBRT dose was 45 Gy and median target volume 16.9 cc. The 1-year local, regional, and distant control was 78%, 66%, and 83%, respectively. Systemic therapy improved regional (p = 0.004) and distant control (p = 0.04) in nonmetastatic patients. Grade 3+ toxicities were more common at mucosal sites (p = 0.001) and with concurrent systemic therapy (p = 0.02). Conclusions: In a large cohort of SBRT reirradiation for recurrent, small volume head and neck cancers, a median OS of 44.3 months was observed. Systemic therapy improved regional and distant control. Toxicities were modulated by anatomic site and systemic therapy.

Original languageEnglish (US)
Pages (from-to)3331-3344
Number of pages14
JournalHead and Neck
Volume43
Issue number11
DOIs
StatePublished - Nov 2021

Keywords

  • head and neck neoplasms
  • recurrence
  • reirradiation
  • salvage therapy
  • stereotactic body radiotherapy

ASJC Scopus subject areas

  • Otorhinolaryngology

MD Anderson CCSG core facilities

  • Clinical Trials Office

Fingerprint

Dive into the research topics of 'Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: Large, single-institution, modern cohort study'. Together they form a unique fingerprint.

Cite this